StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

Investment analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays reduced their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Stock Performance

NASDAQ CLLS opened at $1.64 on Monday. The firm has a market capitalization of $91.16 million, a P/E ratio of -1.26 and a beta of 3.09. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm’s fifty day moving average price is $1.88 and its two-hundred day moving average price is $2.06. Cellectis has a 1 year low of $1.53 and a 1 year high of $3.73.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same period in the previous year, the company earned ($0.31) earnings per share. As a group, research analysts anticipate that Cellectis will post -0.46 EPS for the current year.

Institutional Trading of Cellectis

Hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. lifted its stake in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares in the last quarter. XTX Topco Ltd bought a new position in Cellectis during the 2nd quarter valued at $29,000. First Affirmative Financial Network bought a new stake in shares of Cellectis in the 3rd quarter worth $45,000. Finally, Long Focus Capital Management LLC lifted its position in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.